首页> 外文期刊>Retina >Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.
【24h】

Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study.

机译:纤溶酶辅助玻璃体切除术治疗增生性糖尿病视网膜病变的增生膜:一项初步研究。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To demonstrate the feasibility of autologous plasmin for treatment of proliferative diabetic retinopathy. METHODS: The study examined prospectively six patients with bilateral proliferative diabetic retinopathy. Comparisons of the surgical time and the incidence of retinal tears were made between the eyes treated with autologous plasmin and their respective opposite eyes, which were treated without plasmin. RESULTS: All eyes treated with autologous plasmin required significantly less surgical time (68 versus 89 minutes, P = 0.04, paired t-test). In the plasmin group, no additional surgical procedures for removing the proliferative membrane were needed, including membrane delamination or segmentation. Moreover, with plasmin pretreatment, there were no retinal tears, which was in contrast to the control group, where three eyes with retinal tears were observed. There was no significant difference found between the two groups for final visual outcomes. CONCLUSION: Autologous plasmin may be beneficial in the surgical management of proliferative diabetic retinopathy.
机译:目的:证明自体纤溶酶治疗增生性糖尿病视网膜病变的可行性。方法:该研究前瞻性检查了6例双侧增生性糖尿病视网膜病变患者。比较接受自体纤溶酶治疗的眼睛和未接受纤溶酶治疗的对侧眼睛的手术时间和视网膜泪液的发生率。结果:所有接受自体纤溶酶治疗的眼睛所需的手术时间均显着减少(68对89分钟,P = 0.04,配对t检验)。在纤溶酶组中,不需要额外的手术步骤来去除增生膜,包括膜分层或分割。而且,通过纤溶酶预处理,没有视网膜裂孔,这与对照组观察到三只眼睛有视网膜裂孔的对照组相反。两组的最终视觉效果没有显着差异。结论:自体纤溶酶可能对增生性糖尿病视网膜病变的手术治疗有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号